Ashton Tweed Connection Vol. 3 No. 8

Featuring CEO Interview with Philip M. Sass, Chairman, President & CEO, Liquid Biotech USA, Inc.

Volume 3, Number 8

Whether you are or you require executive or management talent — interim, permanent, or interim to hire — Ashton Tweed can meet your specialized retained search and executive search needs.

CEO Leadership Series: Philip M. Sass, Chairman, President & CEO, Liquid Biotech USA, Inc.

After co-founding and building Morphotek, Inc., a biotech company that specializes in developing biologics for the treatment of oncology, infectious and autoimmune diseases, and selling it to Eisai Co. Ltd., a Japanese firm, for $325 million in 2007, Dr. Philip M. Sass stayed with Eisai for seven years before looking for a new opportunity. He’s now embarked on his next challenge at the helm of Liquid Biotech USA Inc…

Senior Product Manager Kicks Off New Division

A well-established medical device company was starting up a new electronics division as part of the company’s growth plan. The first hire in this new division would be a Senior Product Manager. Busy preparing the company for the expansion, the client had little time to spare to complete an extensive and successful search for this new member. Instead, they placed their trust in the hands of Ashton Tweed to fill…

Beating the Regulation Rush With Interim Executives

My client, a biologics company, began preparing its Investigational New Drug (IND) application, but needed help from a regulatory professional who had biologics experience. At such a small company, the CEO didn’t feel the need to hire a permanent employee to help handle the IND submission. Instead, the company hired interim talent. Regulations are constantly being added and amended in the life sciences industry…


	Your Top Life Sciences Hiring News! Subscribe Today for Ashton Tweed’s Weekly Digest Emails that cover hiring, firing, and retiring news in the Life sciences industry:

Big Pharma’s big question: Is Trump friend or foe?

Trump wants Medicare to directly negotiate the prices it pays for prescription drugs, endorses price transparency, and supports drugs being imported from other countries – all policies opposed by drug makers. Not to mention he’s vowed to take on the pharma lobby… Others expect Trump to govern like a traditional Republican.

Chinese scientists become first to test CRISPR in humans

China has beaten the U.S. in becoming the first to test CRISPR-Cas9 in humans. Reported in the Nature journal, scientists led by Lu You at Sichuan University in Chengdu, injected modified cells using CRISPR into a patient with lung cancer at the West China Hospital. The team plans to treat 10 people with a series of injections…

The ENDPOINTS 100 Survey

Endpoints News’ first quarterly confidence survey of the global biotech industry surveyed a group of biotech CEOs, C-suite execs and VCs on a variety of biotech boards in the U.S. and Europe. In the survey, they share their views on access to capital, hiring, valuations, the regulatory environment, outsourcing, pricing, and the U.S. presidential election…

Fierce Women in Biopharma

2016 has been a trailblazing year for women in biopharma! Emma Walmsley, whom was featured on this list last year, was selected as the next CEO of GlaxoSmithKline, making her the first woman to lead a Big Pharma company. But she’s not the first woman to make a major impact on her company or industry. This year, FiercePharma features…

PCCI’s 10th Annual Grand Meeting: Pitch Perfect (“Beyond the A round”)

Monday, December 12, 2016, 6PM in Wayne, PA

PCCI has put out a BOLO and an APB for four of the area’s most fundable pre and/or post revenue life science companies. They will compete in a “pitch-off” in front of a panel of four investors who are actively seeking fundable assets and may invest if the opportunity is right.

Atlas, Third Rock launch biotech

Atlas Venture and Third Rock Ventures have teamed up to launch new Cambridge biotech Magenta Therapeutics, which will focus on improving bone marrow transplants. They recently unveiled a $48.5M round of financing. Magenta will be led by Jason Gardner, the former head of GSK’s R&D…

What’s up with Apple in healthcare?

Recently, Apple has been making moves suggesting a major thrust into healthcare. They have forged a clinical trial partnership with Beth Israel Deaconess Hospital and a precision medicine initiative with Scripps Translational Science Institute. Apple has also partnered with IBM, J&J, and Medtronic on Watson…